Where We Aim to Innovate

Curacle addresses the common pathology of endothelial dysfunction, pioneering new treatmentparadigms across the eye, kidney, brain, cardiovascular, and inflammatory diseases.
Retinal diseases
Kidney diseases
Neurovascular disorders
Ischemic/Thrombotic diseases
Intractable inflammatory diseases
Pipeline Indication Ad Route Key Features Development Status Discovery Pre-
Clinical		 Phase 1 Phase 2 Phase 3 Launch Partner
IIa IIb
Rivasterat (CU06) DME(Diabetic Macular Edema) / Wet-AMD(Age-related Macular Degeneration) PO First oral endothelial dysfunction blocker Completed Phase 2a clinical trial in the U.S(2024.1Q)
CU01 DN(Diabetic Nephropathy) PO Nrf2-activating, TGF-β-inhibiting therapy Phase 2b clinical trial in Korea completed
MT-101 AKI(Acute Kidney Injury)/ CKD(Chronic Kidney Disease) IV Tie2-activating antibody Preclinical studies in progress
MT-103 Wet-AMD / DME / DR(Diabetic Retinopathy) IV Tie2-activating x anti-VEGF(Bi-specific antibody) Preclinical studies in progress
MT-105 IBD(Inflammatory Bowel Disease) IV trispecific antibody Discovery
MT-201 DVT(Deep Vein Thrombosis) / PE(Pulmonary Embolism) IV Non bleeding anti-thrombotic antibody Preclinical studies in progress
MT-202 AIS(Acute Ischemic Stroke) / HFpEF(Heart Failure with preserved Ejection Fraction) IV Non-bleeding anti-thrombotic × Tie2-activating (bispecific antibody) Preclinical studies in progress
CU71 AD(Alzheimer’s Disease) PO Next-generation endothelial dysfunction blocker Preclinical studies in progress
CP01-R01 Kidney Failure in Companion Animals PO Confirmed therapeutic effects on kidney disease in animal models Phase 3 clinical trial in dogs ongoing (Korea)
CU104 UC(Ulcerative Colitis) PO Indication expansion of CU06 Completed Phase 1 clinical trial in the U.S
CU106 Immuno-Oncology combination PO Indication expansion of CU06 Completed Phase 1 clinical trial in the U.S

Rivasterat (CU06)

The first oral Endothelial Dysfunction Blocker.
Phase 2a in DME demonstrated vision improvement and safety, emerging as a next-generation oral therapy.

CU01

A dual-function therapy targeting NRF2 activation and TGF-β inhibition.
Phase 2 in diabetic nephropathy confirmed safety and GFR improvement, advancing as a next-generation renal therapy.

MT-101

The first fully humanized Tie2 agonist antibody.
Directly activates renal vasculature to reduce inflammation and fibrosis, emerging as an innovative therapy for AKI and CKD.

MT-103

The first bispecific antibody combining Tie2 agonist and anti-VEGF functions. Unlike Vabysmo, MT-103 directly activates Tie2 and has shown superior preclinical efficacy, defining a next-generation therapy for retinal diseases.

MT-105

Tie2-based trispecific antibody targeting IBD

MT-201

A non-bleeding anti-thrombotic antibody targeting PD-X.
Inhibits and dissolves clots in VTE and PE without bleeding risk, advancing as a next-generation anti-thrombotic therapy.

MT-202

A dual-mechanism therapy combining PD-X inhibition and Tie2 agonism.
Provides endothelial protection and anti-thrombotic efficacy in ischemia/reperfusion injury, developed as an innovative combined therapy.

CU71

Next-generation Neurovascular Stabilizer.
Targets BBB dysfunction and neuroinflammation, positioned as an innovative candidate for Alzheimer's, small vessel disease, and vascular dementia.

CP01-R01

First oral endothelial stabilizer–based candidate for companion animal CKD therapy.